Detail akcie Blueprint Med online

Business Summary: Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Blueprint Medicines Corp revenues increased from $249.4M to $508.8M. Net loss decreased 87% to $67.1M. Revenues reflect Product revenue, net increase from $204.2M to $479M. Lower net loss reflects Biopharmaceutical segment loss decrease of 56% to $212M. Basic Earnings per Share excluding Extraordinary Items increased from -$8.37 to -$1.07.